A weekly round-up of the
latest coverage in psychedelics.
Receive the free weekly digest straight to your inbox every week
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
February 17 – 23, 2025
Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics
Psychedelic Alpha ↗
Hailey Gilmore, MPH explores how PrEP’s rollout offers key learnings for the medicalization of psychedelics, particularly in overcoming stigma, building provider awareness, and integrating new treatments into existing healthcare structures.
New Course for Current Students and Practicing Clinical Social Workers: Principles of Psychedelic Healing
UWisc School of Social Work ↗
February 10 – 16, 2025
Psychedelic Bulletin 188
Psychedelic Alpha ↗
- Q4’24: Federal Psychedelics Lobbying Update
- GH Research Discusses Lack of Placebo Effect, Decision to Keep Trial Sites Secret
- Virginia Lawmakers Question Purpose and Precedent of Compass Pathways’ Rescheduling Bill
- VA Psychedelics Champion Leaves Post
- Colorado’s Psychedelics Program Sees Slow Start
- Lykos’ FDA Rejection in Context
- Center for MINDS Backs Psilocybin for Creativity Study
- Study Reveals Differing Views on Psychological Support
- and much more…
Psychedelic-assisted therapy for mental health: Policy considerations
UK Parliamentary Office of Science and Technology ↗
Psychedelics and the Future of Mental Health: Science, Faith, Hype and Healthcare Innovation with Fayzan Rob
Health is Everything Podcast ↗
When The Smoke Clears
LA Times (via YouTube) ↗
An LA Times short documentary will premiere on February 18th. It follows two first responders who travel to Mexico to undergo psychedelic therapy in the hopes it will help their PTSD and depression.
February 3 – 9, 2025
This Week’s Feed, Sponsored by
ISRP 2025 International Society for Research on Psychedelics - Virtual conference
The International Society for Research on Psychedelics (ISRP) is hosting a virtual conference on March 7, 2025 that features more than twenty 15-minute presentations on the latest developments in the field. The full-day agenda spans pre-clinical science, observational research, and clinical studies.
Should you face barriers to attendance, the conference organisers invite you to apply for registration fee assistance.
Pα+ Psychedelic Bulletin #187
Psychedelic Alpha ↗
- The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
- Mixed Messages on Psymposia’s Role
- Lykos and MAPS Seize the Opportunity
- Political Pragmatism Sparks Backlash Among Some Supporters
- Psychedelic Drug Developers Reflect on “Lykos-Specific Issues” and the Road Ahead
- FDA “Wanted to Approve” MDMA, Says MindMed Exec
- Trump on Psychedelics; “Nothing” Lies Beyond Psychological Support; Trial Site Availability Limits Psychedelic Drug Development
- GH’s 5-MeO-DMT Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring
- and much more…
Meet the Cambridge researchers exploring psychedelic-assisted therapies
Varsity ↗
See also an event, Cambridge Psychedelic Research Day, March 12th, 2025.
A New Model for Psychiatric Care at Johns Hopkins
Johns Hopkins Medicine ↗
Johns Hopkins opens the first clinic of its kind in the U.S. which aims to support individuals experiencing difficulties following a psychedelic experience.
January 27 – February 2, 2025
Q1’25 Bullseye: The Psychedelic Drug Development Pipeline
Psychedelic Alpha ↗
Explore the latest edition of our Bullseye Chart, which displays psychedelic candidates by phase of development and molecule type.
Updated: The Psychedelic Drug Development Tracker
Psychedelic Alpha ↗
We have also updated the Tracker webpage, where you can explore psychedelic candidates by stage of development.
2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis
Psychedelic Alpha ↗
Here, we parse through the influx of new bills. First, Psychedelic Alpha Editor Josh Hardman provides a high-level thematic overview of the fresh set of bills. Then, Jack Gorsline runs through the bills one by one.
Covering psychedelics: dispatches from the front-lines of psychedelic journalism’
YouTube ↗
With Shayla Love of the Atlantic, Josh Hardman of Psychedelic Alpha, Mattha Busby of Vice and Rolling Stone, and Jack Gorsline.
Beckley Psytech announces positive topline data from Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder
Press Release ↗
Beckley’s open-label study (n=12) of its intranasal 5-MeO-DMT candidate in AUD reports 50% of participants completely abstinent at 3 months.
Event: Matrix on Point: Mainstreaming Psychedelics
Berkeley Events ↗
Ft. Psychedelic Alpha Editor-at-Large Graham Pechenik.
February 1-7, 2025
Pα+
An insider’s guide to the business,
policy and science of psychedelics.
Basic
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||